Josefin Fernebro
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Functional profiling of ovarian cancer models reveals Bcl-xL/NOTCH targeting to overcome resistance.
Functional profiling of ovarian cancer models reveals Bcl-xL/NOTCH targeting to overcome resistance.
Journal: NPJ precision oncology
Published: March 26, 2026
Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving field.
Journal: Journal of internal medicine
Published: February 14, 2026
Protocol for culture, drug treatment, and dissociation of patient-derived 3D ovarian cancer microspheroids for flow cytometry.
Journal: STAR protocols
Published: November 28, 2025
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.
Journal: Gynecologic oncology
Published: February 04, 2025
Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer.
Journal: Molecular oncology
Published: October 22, 2024
High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.
Journal: Gynecologic oncology
Published: August 13, 2024
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: March 20, 2024
Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 19, 2024
The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients.
Journal: NPJ precision oncology
Published: March 27, 2023
Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor.
Journal: Advances in therapy
Published: August 13, 2020
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
Journal: Gynecologic oncology
Published: May 11, 2020
Showing 1-12 of 12
Last Updated: 09/26/2026